Mesenchymal stem cells and management of COVID-19 pneumonia

Metcalfe, Su

doi:10.1016/j.medidd.2020.100019

Cited by 132 publications

(146 citation statements)

References 8 publications

(5 reference statements)

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…The current hallmark of SARS-CoV-2 pathogenesis is the cytokine storm in the lung. Virally-triggered acute cytokine release of GSCF, IP10, MCP1, MIP1A, IL-2, IL-6, IL-7, and TNF results in pulmonary edema, dysfunction of air-exchange, acute respiratory distress syndrome (ARDS), and acute cardiac injury, and leading to death [2].…”

Section: Sars-cov-2 and Covid-19mentioning

confidence: 99%

“…According to a recent announcement of the International Society for Stem Cell Research (ISSCR), currently, there are no approved stem cell-based approaches for the prevention and treatment of COVID-19 infection. However, recently, mesenchymal stem cells (MSCs) have introduced one of the therapeutic approaches for using in the treatment of COVID-19 [2]. As we know, MSCs opposes viral infection due to the presence of specific cytokines improved qualities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

295

302

View full text Add to dashboard Cite

" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.

show abstract

Section: Sars-cov-2 and Covid-19mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

295

302

View full text Add to dashboard Cite

show abstract

“…Although allogeneic bone marrow mesenchymal stem cell (bmMSC) transplantation has shown promise, with trials currently underway, this technology is limited by safety, cell survivability, scalability, and regulatory issues that make it an impractical option to meet the needs of millions of infected patients worldwide [12][13][14]. However, bone marrow derived exosomes, a complex mix of signaling nanovesicles secreted by bmMSCs, are a novel, multitargeted, next generation biologic agent that could be the key to downregulating the cytokine storm, and to reversing the suppression of host antiviral defenses that characterize COVID-19 [15].…”

Section: Introductionmentioning

confidence: 99%

Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

Sengupta

Lazo

et al. 2020

Stem Cells and Development

544

492

View full text Add to dashboard Cite

This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFloÔ) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO 2 / FiO 2 ) increase of 192% (P < 0.001). Laboratory values revealed significant improvements in absolute neutrophil count [mean reduction 32% (P value <0.001)] and lymphopenia with average CD3 + , CD4 + , and CD8 + lymphocyte counts increasing by 46% (P < 0.05), 45% (P < 0.05), and 46% (P < 0.001), respectively. Likewise, acute phase reactants declined, with mean C-reactive protein, ferritin, and D-dimer reduction of 77% (P < 0.001), 43% (P < 0.001), and 42% (P < 0.05), respectively. In conclusion, owing to its safety profile, capacity to restore oxygenation, downregulate cytokine storm, and reconstitute immunity, ExoFlo is a promising therapeutic candidate for severe COVID-19. Future randomized controlled trials (RCTs) are needed to determine ExoFlo therapeutic potential.

show abstract

“…[26] Novel therapies such as interleukin (IL) antagonists (dupilumab), JAK2 inhibitor (fetratinib), interferon blockers (e.g., entecavir, penciclovir, sorafenib), and stem cell and mesenchymal cell therapies have been applied to neutralize cytokine storm and offered some improvement. [26][27][28] Major surgery and anesthesia produce inflammatory and immune response in human beings. In addition, extracorporeal circulation has been presented to be the cause of the main immune response during cardiac surgery.…”

Section: And Further Potential Effects Of Cardiac Surgerymentioning

confidence: 99%

Perioperative planning for cardiovascular operations in the COVID-19 pandemic

Mavioğlu¹

2020

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

ÖZKoronavirüs hastalığı-2019 (COVID-19) tüm dünyada sağlık çalışanlarını alarm durumuna geçiren ciddi bir sağlık sorunudur. Pandeminin beraberinde getirmiş olduğu ve sağlık sistemini ilgilendiren ele alınması gereken iki önemli konu mevcuttur. Birincisi; pandeminin yayılma hızına yetişme sıkıntısı çekebilecek olan sağlık sisteminin yükünü azaltabilmek açısından elektif birçok işlemin/cerrahinin ertelenmesi gerekliliğidir. Bu nedenle, cerrahi gereken kardiyovasküler hastalıkların önceliğinin ve ertelenebilirliğinin belirlenmesi için "Öncelik Düzeyi" olarak adlandırdığımız bir algoritma geliştirilmesini amaçladık. İkinci olarak ise; kardiyovasküler cerrahi yapılması gereken acil ve öncelikli hastalarda cerrahinin ve sonrasında yoğun bakım ünitesinde takibinin, enfeksiyon koruma tedbirlerinin sağlandığı bir ortamda yapılması gerekliliğidir. Bu yazıda, hasta güvenliğinin sağlanabilmesi ve cerrahi ekibin maksimum seviyede korunabilmesi için uygulanabilecek olan gerekli tedbirler sunuldu. ABSTRACTCoronavirus disease-2019 (COVID-19) is a serious health concern which alert all healthcare professionals worldwide. There are two main issues caused by this pandemic regarding for the healthcare system. First, it is a necessity to postpone many elective procedures/surgeries to reduce the burden of the healthcare system which may be confronted with strain by the increased speed of transmission. Therefore, we aimed to develop an algorithm called as Level of Priority to identify the priority and deferrability of cardiovascular diseases requiring surgery. Second, it is essential to perform surgery and intensive care unit follow-up in a setting where the infection prevention measures are followed for primary patients requiring emergency cardiovascular surgery. In this article, we present necessary precautions to be exercised to provide the patient safety and the highest level of protection for the surgical team.

show abstract

Mesenchymal stem cells and management of COVID-19 pneumonia

Cited by 132 publications

References 8 publications

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

Perioperative planning for cardiovascular operations in the COVID-19 pandemic

Contact Info

Product

Resources

About